Trevi Therapeutics Company Top Insiders
TRVI Stock | USD 4.51 0.01 0.22% |
Trevi Therapeutics' insiders are aggressively selling. The analysis of insiders' sentiment of trading Trevi Therapeutics stock suggests that almost all insiders are panicking at this time. Trevi Therapeutics employs about 27 people. The company is managed by 9 executives with a total tenure of roughly 63 years, averaging almost 7.0 years of service per executive, having 3.0 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
2024-09-09 | Jennifer L Good | Disposed 1840 @ 3.04 | View | ||
2024-09-06 | Jennifer L Good | Disposed 4219 @ 3.03 | View | ||
2024-09-04 | Jennifer L Good | Disposed 10981 @ 3.02 | View | ||
2024-08-27 | David P Meeker | Disposed 4555 @ 2.93 | View | ||
2024-08-16 | Thomas Sciascia | Disposed 18660 @ 2.76 | View | ||
2024-08-14 | Thomas Sciascia | Disposed 100 @ 2.75 | View | ||
2024-05-29 | Thomas Sciascia | Disposed 53368 @ 2.55 | View | ||
2024-05-22 | Lisa Delfini | Disposed 4350 @ 2.64 | View | ||
2024-05-20 | Jennifer L Good | Disposed 25037 @ 2.86 | View | ||
2024-05-10 | Jennifer L Good | Disposed 4578 @ 2.9 | View |
Monitoring Trevi Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Trevi |
Trevi Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Trevi Therapeutics' future performance. Based on our forecasts, it is anticipated that Trevi will maintain a workforce of under 30 employees by March 2025.Trevi Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3657) % which means that it has lost $0.3657 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5965) %, meaning that it created substantial loss on money invested by shareholders. Trevi Therapeutics' management efficiency ratios could be used to measure how well Trevi Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.31. The current Return On Capital Employed is estimated to decrease to -0.49. As of now, Trevi Therapeutics' Non Currrent Assets Other are increasing as compared to previous years.The Trevi Therapeutics' current Common Stock Shares Outstanding is estimated to increase to about 119.6 M, while Net Loss is projected to decrease to (27.5 M).
Trevi Therapeutics Workforce Comparison
Trevi Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,976. Trevi Therapeutics claims roughly 27.0 in number of employees contributing just under 2% to equities under Health Care industry.
Trevi Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Trevi Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Trevi Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Trevi Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 4.0 | 8 | 2 | 1,682,500 | 6,000 |
2024-12-01 | 1.0 | 1 | 1 | 15,000 | 15,000 |
2024-09-01 | 0.55 | 11 | 20 | 513,736 | 227,472 |
2024-06-01 | 1.25 | 10 | 8 | 285,012 | 192,345 |
2023-12-01 | 0.5 | 1 | 2 | 2,292 | 3,077 |
2023-09-01 | 0.5 | 3 | 6 | 6,875 | 8,955 |
2023-06-01 | 1.4286 | 10 | 7 | 193,124 | 15,136 |
2023-03-01 | 0.8889 | 8 | 9 | 938,541 | 225,407 |
2022-09-01 | 0.6667 | 2 | 3 | 39,500 | 563,569 |
2022-06-01 | 5.375 | 43 | 8 | 61,317,260 | 562,891 |
2020-06-01 | 0.7273 | 16 | 22 | 15,081,088 | 16,505,641 |
2019-06-01 | 0.798 | 79 | 99 | 65,537,969 | 284,103,609 |
Trevi Therapeutics Notable Stakeholders
A Trevi Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Trevi Therapeutics often face trade-offs trying to please all of them. Trevi Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Trevi Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
James Cassella | Chief Director | Profile | |
Farrell PharmD | Chief Officer | Profile | |
Christopher Galletta | Controller Officer | Profile | |
AFPM MD | Chief Officer | Profile | |
Danine Summers | Vice Affairs | Profile | |
Lisa Delfini | Chief Officer | Profile | |
Jennifer Good | CEO, CoFounder | Profile | |
Thomas MD | CoFounder Officer | Profile | |
Katie McManus | Communications Manager | Profile |
About Trevi Therapeutics Management Performance
The success or failure of an entity such as Trevi Therapeutics often depends on how effective the management is. Trevi Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Trevi management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Trevi management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.29) | (0.31) | |
Return On Capital Employed | (0.47) | (0.49) | |
Return On Assets | (0.29) | (0.31) | |
Return On Equity | (0.40) | (0.43) |
Trevi Therapeutics Workforce Analysis
Traditionally, organizations such as Trevi Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Trevi Therapeutics within its industry.Trevi Therapeutics Manpower Efficiency
Return on Trevi Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.1M | |
Net Loss Per Executive | 3.2M | |
Working Capital Per Employee | 3M | |
Working Capital Per Executive | 9.1M |
Complementary Tools for Trevi Stock analysis
When running Trevi Therapeutics' price analysis, check to measure Trevi Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trevi Therapeutics is operating at the current time. Most of Trevi Therapeutics' value examination focuses on studying past and present price action to predict the probability of Trevi Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trevi Therapeutics' price. Additionally, you may evaluate how the addition of Trevi Therapeutics to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |